ZNF217 promoted oncogenic phenotypes in all the cell lines we have tested so far suggesting that ZNF217 can impact tumor progression in a broad spectrum of ovarian cancer patients with tumors that differ in their p53 status. Here, TP53 is linked to ovarian carcinoma.